表紙
市場調査レポート

嚢胞性線維症の世界市場

Global Cystic Fibrosis Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 321449
出版日 ページ情報 英文 126 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
嚢胞性線維症の世界市場 Global Cystic Fibrosis Market 2015-2019
出版日: 2014年12月17日 ページ情報: 英文 126 Pages
概要

嚢胞性線維症は、コーカサス人の子供によく見られる遺伝性疾患の一種です。発生率は集団により様々で、欧州や北米のコーカサス系の人種に比べ、アジア人やアフリカ人にはあまり見られない疾患となっております。世界の嚢胞性線維症市場は2014年〜2019年の間にCAGRが32.50%成長する見込みとなっております。

当レポートでは世界の嚢胞性線維症市場について調査分析を行い、市場概要、セグメンテーション別考察、地域市場の状況、市場促進因子、市場の課題、ベンダー分析などについてまとめています。

第1章 エグゼクティブサマリー

第2章 略語一覧

第3章 本レポートの範囲

  • 市場概要
  • 商品

第4章 製品のプロファイル

第5章 市場調査方法

  • 市場調査のプロセス
  • 調査方法

第6章 イントロダクション

第7章 疾患の概要

  • 疾患の理解
  • 病態生理
  • 疫学
  • 診断
  • 嚢胞性線維症の兆候
  • 経済的負担

第8章 市場の状況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第9章 市場のセグメンテーション:分子別

  • 生物
  • 小分子

第10章 市場のセグメンテーション:薬の投与経路別

  • 経口
  • 非経口
  • 局所

第11章 市場のセグメンテーション:剤形別

  • 固体
  • 液体

第12章 地域別セグメンテーション

  • 南北アメリカ
  • EMEA
  • アジア太平洋地域

第13章 主要国

  • 米国
  • 英国
  • フランス
  • カナダ
  • イタリア

第14章 購買基準

第15章 市場成長促進因子

第16章 市場促進因子とその影響

第17章 市場の課題

第18章 促進因子と課題の影響

第19章 市場動向

第20章 動向とその影響

第21章 ベンダーの状況

  • 競合シナリオ
  • 市場シェア分析
  • その他の/今後の主要ベンダー

第22章 主要ベンダー分析

  • Actavis
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals

第23章 本シリーズのその他のレポート

図表

目次
Product Code: IRTNTR4842

About Cystic Fibrosis

Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country.

Cystic fibrosis is a chronic disease. The production of a high-salt containing sweat and secretion of abnormal viscous mucus are the major symptoms of cystic fibrosis.

TechNavio's analysts forecast the Global Cystic Fibrosis market to grow at a CAGR of 32.50 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Cystic Fibrosis market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis which includes:

  • Small Molecules
  • Biologics

Further, the market is segmented on based on route of administration and dosage form. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cystic Fibrosis market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Cystic Fibrosis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA region; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actavis
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Anthera Pharmaceuticals
  • Arcturus Therapeutics
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Insmed
  • Pharmaxis
  • PharmaSwiss
  • Genzyme
  • Johnson & Johnson
  • Merck Sharp & Dohme
  • Neovii Biotech
  • Novo Nordisk
  • Proteostasis Therapeutics
  • PTC Therapeutics
  • United Medical
  • Venus Remedies

Market Driver

  • Unmet Needs in the Market
  • For a full, detailed list, view our report

Market Challenge

  • Expensive Treatment
  • For a full, detailed list, view our report

Market Trend

  • Increase in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Zenpep/ Ultresa/ Ultrase/ Ultrase MT
    • 04.1.2. Colomycin/ Colobreathe
    • 04.1.3. Pulmozyme
    • 04.1.4. Cayston
    • 04.1.5. TOBI/ TOBI Podhaler
    • 04.1.6. Kalydeco

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
  • 07.2. Pathophysiology
  • 07.3. Epidemiology
    • 07.3.1. Global
    • 07.3.2. North America
    • 07.3.3. Europe
    • 07.3.4. Africas
    • 07.3.5. Latin America
    • 07.3.6. Middle East
    • 07.3.7. Asia and Oceania
  • 07.4. Diagnosis
    • 07.4.1. Newborn Screening
    • 07.4.2. Carrier Testing
    • 07.4.3. Antenatal Testing
    • 07.4.4. Other Tests
  • 07.5. Manifestations of Cystic Fibrosis
  • 07.6. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Molecule Type

  • 09.1. Biologics
    • 09.1.1. Enzymes
  • 09.2. Small Molecules
    • 09.2.1. CFTR Modulator
    • 09.2.2. Antibiotics

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

  • 12.1. Cystic Fibrosis Market in the Americas
    • 12.1.1. Cystic Fibrosis Market in the US
    • 12.1.2. Cystic Fibrosis Market in the Latin America
    • 12.1.3. Cystic Fibrosis Market in the Canada
  • 12.2. Cystic Fibrosis Market in the EMEA Region
    • 12.2.1. Market Size and Forecast
  • 12.3. Cystic Fibrosis Market in the APAC Region
    • 12.3.1. Market Size and Forecast

13. Key Leading Countries

  • 13.1. US
  • 13.2. UK
  • 13.3. France
  • 13.4. Canada
  • 13.5. Italy

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. F. Hoffmann-La Roche
    • 21.2.2. Novartis
    • 21.2.3. Vertex Pharmaceuticals
    • 21.2.4. Actavis
    • 21.2.5. Gilead Sciences
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Actavis
    • 22.1.1. Key Facts
    • 22.1.2. Business Description
    • 22.1.3. Business Segmentation
    • 21.1.4. Revenue by Business Segmentation
    • 22.1.5. Revenue Comparison 2013 and 2014
    • 22.1.6. Sales by Geography
    • 22.1.7. Business Strategy
    • 22.1.8. Key Developments
    • 22.1.9. SWOT Analysis
  • 22.2. F. Hoffmann-La Roche
    • 22.2.1. Key Facts
    • 22.2.2. Business Description
    • 22.2.3. Business Segmentation
    • 22.2.4. Revenue by Business Segmentation
    • 22.2.5. Revenue Comparison 2013 and 2014
    • 22.2.6. Sales by Geography
    • 22.2.7. Business Strategy
    • 22.2.8. Key Developments
    • 22.1.9. SWOT Analysis
  • 22.3. Gilead Sciences
    • 22.3.1. Key Facts
    • 22.3.2. Business Description
    • 22.3.3. Business Segmentation
    • 22.3.4. Revenue by Business Segmentation
    • 22.3.5. Revenue Comparison 2013 and 2014
    • 22.3.6. Sales by Geography
    • 22.3.7. Business Strategy
    • 22.3.8. Key Developments
    • 22.3.9. SWOT Analysis
  • 22.4. Novartis
    • 22.4.1. Key Facts
    • 22.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 22.4.4. Revenue by Business Segmentation
    • 22.4.5. Revenue Comparison 2013 and 2014
    • 22.4.6. Sales by Geography
    • 22.4.7. Business Strategy
    • 22.4.8. Key Developments
    • 22.4.9. SWOT Analysis
  • 22.5. Vertex Pharmaceuticals
    • 22.5.1. Key Facts
    • 22.5.2. Business Description
    • 22.5.3. Business Segmentation
    • 22.5.4. Revenue by Business Segmentation
    • 22.5.5. Revenue Comparison 2013 and 2014
    • 22.5.6. Sales by Geography
    • 22.5.7. Business Strategy
    • 22.5.8. Key Developments
    • 22.5.9. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot Of Cystic Fibrosis Disease
  • Exhibit 3: Defects Caused by CFTR Mutation
  • Exhibit 4: Epidemiology of Cystic Fibrosis in the World 2012
  • Exhibit 5: Prevalence of Cystic Fibrosis by Country 2014
  • Exhibit 6: Prevalence Number of Cystic Fibrosis by Country 2014
  • Exhibit 7: Snapshot of US Prevalence of Cystic Fibrosis 2014
  • Exhibit 8: Forecast of Cystic Fibrosis Prevalence in US 2014-2019
  • Exhibit 9: Epidemiology Based on the Education Level in US, 2011
  • Exhibit 10: Epidemiology based on the Marital Status in US, 2011
  • Exhibit 11: Epidemiology based on the Employment Status in US, 2011
  • Exhibit 12: Forecast of Cystic Fibrosis Prevalence in Canada 2014-2019
  • Exhibit 13: Forecast of Cystic Fibrosis Prevalence in the UK 2014-2019
  • Exhibit 14: Age Distribution at Death for Cystic Fibrosis Patients in UK, 2013
  • Exhibit 15: Age Distribution by Gender for Cystic Fibrosis Patients in the UK, 2013
  • Exhibit 16: Age Distribution by Sex for Cystic Fibrosis Patients in the UK, 2013
  • Exhibit 17: Diagnosis of Cystic Fibrosis
  • Exhibit 18: The Manifestations of Cystic Fibrosis
  • Exhibit 19: Snapshot of the Economic Burden of Cystic Fibrosis
  • Exhibit 20: Snapshot of Global Cystic Fibrosis Market 2014
  • Exhibit 21: Global Cystic Fibrosis Market 2014-2019 (US$ million)
  • Exhibit 22: Global Cystic Fibrosis Market Segmentation By Class of Drugs
  • Exhibit 23: Global Cystic Fibrosis Drugs Market Segmentation by Molecule Type 2014
  • Exhibit 24: Global Cystic Fibrosis Market Segmentation By Route Of Administration
  • Exhibit 25: Global Cystic Fibrosis Drugs Market Segmentation by Route of Administration 2014
  • Exhibit 26: Global Cystic Fibrosis Market Segmentation by Dosage Form
  • Exhibit 27: Global Cystic Fibrosis Drugs Market Segmentation by Dosage Form 2014
  • Exhibit 28: Global Cystic Fibrosis Market by Geographical Segmentation 2014 and 2019
  • Exhibit 29: Global Cystic Fibrosis Market Revenue by Geographical Segmentation 2014-2019 (US$ million)
  • Exhibit 30: Global Cystic Fibrosis Market Growth Rate by Region 2014-2019
  • Exhibit 31: Revenue (US$ million) and CAGR of Global Cystic Fibrosis Market by Geographical Segments 2014 and 2019
  • Exhibit 32: Global Cystic Fibrosis Market by Country/Region 2014
  • Exhibit 33: Global Cystic Fibrosis Market by Country/Region 2014 (US$ million)
  • Exhibit 34: Cystic Fibrosis Market in the Americas 2014-2019 (US$ million)
  • Exhibit 35: Cystic Fibrosis Market Revenue in the Americas 2014-2019
  • Exhibit 36: Cystic Fibrosis Market Growth Rate in the Americas 2014-2019
  • Exhibit 37: Cystic Fibrosis Market in the Americas by Region 2014 and 2019
  • Exhibit 38: Revenue (US$ million) and CAGR of Cystic Fibrosis Market in the Americas by Regions 2014 and 2019
  • Exhibit 39: Cystic Fibrosis Market in the US 2014-2019 (US$ million)
  • Exhibit 40: Cystic Fibrosis Market in the Latin America 2014-2019 (US$ million)
  • Exhibit 41: Cystic Fibrosis Market in Canada 2014-2019 (US$ million)
  • Exhibit 42: Cystic Fibrosis Market in EMEA 2014-2019 (US$ million)
  • Exhibit 43: Cystic Fibrosis Market in EMEA by Country/Region 2014
  • Exhibit 44: Cystic Fibrosis Market in APAC 2014-2019 (US$ million)
  • Exhibit 45: Buying Criteria of Global Cystic Fibrosis Market
  • Exhibit 46: Global Cystic Fibrosis Market Share Analysis 2014
  • Exhibit 47: Global Sales Comparison of Pulmozyme 2013 vs 2012 (US$ Million)
  • Exhibit 48: Quarterly Sales Comparison of Pulmozyme in the US 1994-2008 (US$ Million)
  • Exhibit 49: Quarterly Sales Comparison of Pulmozyme Sales to Collaborators 1997-2008 (US$ Million)
  • Exhibit 50: Quarterly Sales Comparison of Pulmozyme Total Sales 1994-2008 (US$ Million)
  • Exhibit 51: Total Global Sales Comparison of Pulmozyme 1994-2008 (US$ Million)
  • Exhibit 52: TOBI Podhaler
  • Exhibit 53: YoY Sales Comparison of TOBI and TOBI Podhaler 2006-2013 (US$ Million)
  • Exhibit 54: YoY Sales Comparison of Kalydeco 2012-2013 (US$ Million)
  • Exhibit 55: Actavis: Business Segmentation 2014
  • Exhibit 56: Actavis: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 57: Actavis : Sales by Geography (in US$ million)
  • Exhibit 67: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2013 and 2014
  • Exhibit 68: F. Hoffmann-La Roche Ltd.: Sales by Geography 2014 (Pharmaceuticals Division)
  • Exhibit 69: F. Hoffmann-La Roche Ltd.: Sales by Geography 2014 (Diagnostics Division)
  • Exhibit 63: Gilead Sciences: Business Segmentation by Revenue 2014
  • Exhibit 64: Gilead Sciences: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 65: Gilead Sciences: Sales by Geography 2014
  • Exhibit 18: Novartis AG: Business Segmentation
  • Exhibit 19: Novartis AG: Revenue by Business Segmentation 2014
  • Exhibit 20: Novartis AG: Revenue by Business Segmentation 2013 and 2014 (US$ million)
  • Exhibit 21: Novartis AG: Revenue by Geographical Segmentation 2014
  • Exhibit 63: Vertex Pharmaceuticals: Business Segmentation by Revenue 2014
  • Exhibit 64: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 65: Vertex Pharmaceuticals: Sales by Geography 2014
Back to Top